A Novel Portable System For Day And Night Closed Loop Automated Insulin Delivery In The Patient With Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$251,133.00
Summary
For patients with Type 1 Diabetes, improved glucose control has been shown to reduce the development of diabetes complications. Although advances have been made in therapy, most people with diabetes do not achieve optimal treatment targets and the burden of care is high. Technologies now exist that allow the development of automatic insulin therapy and the artificial pancreas. These experiments will test a novel portable system that represents a significant step advancing toward this goal.
Type 2 diabetes causes significant health problems. The fundamental reasons underlying this disease are not fully known and will require molecular analysis of proteins critical to blood glucose control. This work aims to define a novel pathway that responds to circulating nutrients. The research will enhance our understanding of the links between diet and metabolic disease, with potential to reveal much needed therapeutic targets and/or dietary interventions for the treatment of Type 2 diabetes.
Closed-loop Insulin Delivery Compared With Islet Cell Transplantation For Adults With Type 1 Diabetes And Impaired Awareness Of Hypoglycaemia
Funder
National Health and Medical Research Council
Funding Amount
$92,745.00
Summary
Hypoglycaemia in adults with type 1 diabetes is common. Evaluation of therapies – the ‘artificial pancreas’ and islet cell transplantation - is warranted in a cohort with repeated episodes of hypoglycaemia. This proposal will assess whether the ‘artificial pancreas’ and islet cell transplantation, compared with usual insulin therapy, will reduce hypoglycaemia and improve other clinical outcomes over 6 months. This has potential to expand therapies used in current clinical practice.
Type 2 diabetes is caused by multiple genetic defects, resulting in high blood sugar levels. These high sugar levels are primarily due to a decrease in the concentration of insulin, a hormone produced by the pancreas. A number of recent studies have aimed to identify which genes are regulated under conditions that mimic diabetes. One gene shown to have altered expression levels under these conditions is an enzyme called fructose-1,6-bisphosphatase (or FBPase). This enzyme is involved in the meta ....Type 2 diabetes is caused by multiple genetic defects, resulting in high blood sugar levels. These high sugar levels are primarily due to a decrease in the concentration of insulin, a hormone produced by the pancreas. A number of recent studies have aimed to identify which genes are regulated under conditions that mimic diabetes. One gene shown to have altered expression levels under these conditions is an enzyme called fructose-1,6-bisphosphatase (or FBPase). This enzyme is involved in the metabolism of sugar and is usually expressed at undetectable levels in the pancreas, but when blood sugar levels are high, the amount of FBPase in the pancreas increases considerably. We hypothesise that this increase in FBPase may contribute to the decrease in insulin secretion by the pancreas, seen in the diabetic state. The aim of this proposal therefore is to study mice that we have modified to express increased FBPase specifically in the pancreas, in order to determine whether this will lead to a decrease in insulin release and to diabetes. If this is the case, then FBPase could be targeted for the development of drugs that would improve the control of blood sugar levels in diabetes.Read moreRead less
Development Of A Specific Activin Antagonist For Therapeutic Applications
Funder
National Health and Medical Research Council
Funding Amount
$504,287.00
Summary
Activin is a key regulator of homeostasis in several organs and tissues, including ovaries, testes, liver and skin, and alterations in activin�s activity can result in fibrosis, cachexia and cancer. In this grant we propose to develop a specific activin antagonist by modifying the activin A propeptide. This novel reagent could be used to promote liver growth in severe hepatic disease and prevent fibrosis in numerous tissues.
Regulation Of Insulin Signalling & Glucose Homeostasis By Protein Tyrosine Phosphatases
Funder
National Health and Medical Research Council
Funding Amount
$503,776.00
Summary
Type 2 diabetes has reached epidemic proportions afflicting roughly 6% of the adult population in Western society. Although the underlying genetic causes and the associated pathological symptoms are heterogenous, a common feature is high blood glucose due to peripheral insulin resistance. The molecular basis of insulin resistance is believed to be attributable to defects in insulin receptor (IR) signalling. The IR is a protein tyrosine kinase that phosphorylates itself and downstream substrates ....Type 2 diabetes has reached epidemic proportions afflicting roughly 6% of the adult population in Western society. Although the underlying genetic causes and the associated pathological symptoms are heterogenous, a common feature is high blood glucose due to peripheral insulin resistance. The molecular basis of insulin resistance is believed to be attributable to defects in insulin receptor (IR) signalling. The IR is a protein tyrosine kinase that phosphorylates itself and downstream substrates on tyrosine in response to insulin. Protein tyrosine phosphatases (PTPs) that dephosphorylate the IR and its substrates might be important targets for therapeutic intervention in type 2 diabetes; inhibition of specific PTPs may allow for enhanced insulin-induced signalling to alleviate insulin resistance. This proposal will examine the roles of PTPs and in particular TCPTP in IR signalling in vivo. Our studies will shed light on the molecular mechanisms of IR regulation and function and may provide important insights into novel strategies for enhancing insulin sensitivity in type 2 diabetes.Read moreRead less